Molecure S.A.

Molecure S.A., a biotech company listed on the Warsaw Stock Exchange under the ticker MOC, focuses on discovering and developing drugs up to the clinical stage. Utilizing unique global expertise in medical chemistry and biology, the firm works on creating first-in-class small molecule drugs. These drugs directly modulate protein activity and mRNA translation to treat various incurable diseases. Molecure has initiated a Phase II clinical trial for OATD-01, targeting patients with active pulmonary sarcoidosis, marking the world's first administration of a Chitotriosidase-1 (CHIT1) inhibitor or placebo, which took place at the Royal Infirmary in Edinburgh.

← Go back